Replies to post #161466 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

Is this a partial explanation for the Exodus of Big Pharma from CNS early this year?

HH serves as Senior Associate Editor for the Journal Alzheimer’s & Dementia; he received
lecture fees from Biogen and Roche, research grants from Pfizer, Avid, and MSD Avenir (paid to
the institution), travel funding from Axovant, Eli Lilly and company, Takeda and Zinfandel, GEHealthcare
and Oryzon Genomics, consultancy fees from Jung Diagnostics, Cytox Ltd., Axovant,
Anavex, Takeda and Zinfandel, GE Healthcare and Oryzon Genomics, and participated in scientific
advisory boards of Axovant, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and
Zinfandel, Oryzon Genomics and Roche Diagnostics.

and

JC has provided consultation to AbbVie, Acadia, Actinogen, Alzheon, Anavex, Avanir,
Axovant, Biogen, Boehinger-Ingelheim, Bracket, Dart, Eisai, Genentech, Kyowa, Lilly, Lundbeck,
Medavante, Merck, Orion, Otsuka, Pfizer, QR, Roche, Suven, and Takeda pharmaceutical and
assessment companies.

[nidan7500]

Doc328:

Its really a Precision Medicine AD article and there is very little about Anavex (or any medication) in long detail. Searching on Anavex gets 3 results. Two are the disclosures for Hampel and Cummings and the third is the Anavex entry in Table 1G Cellular pathway signal modulators. About 100 different drugs are mentioned in the Table 1a to Table 1h.
]

Doc, first of all thanks again for your continuing guidance. Would you comment on the strength of this paper/the body of knowledge represented by this group and what this all means? We have seen the amyloid Thesis fade despite actions of BIIB, and including the embarrassing AAIC2018 press coverages. With that, is this now the new awakening as Precision Medicine hopefully brings some light to an other wise dark field? Are we seeing the "sea change" needed to make progress finally? In that context, is AVXL in the leadership position it appears to be in?